Vice President - Private Shares Trading

Nova Capital acquires BMP Group and RB Medical from Andrew Industries. Nova Capital Management, a private equity firm focused on industrial and specialized manufacturing businesses, has acquired BMP Group and RB Medical from Andrew Industries. The acquired companies will retain their existing management structures, while Nova plans to provide strategic, financial and operational support aimed at investment, operational improvement, product development and growth. BMP Group manufactures industrial consumable parts and sub-assemblies for applications spanning office automation, filtration, automotive, domestic appliances, sustainable tree protection and renewable energy. RB Medical is a specialized healthcare products business serving the U.K. medical sector. Nova plans to work with the existing management teams on strategy, performance and investment, with Omiros Millas, a partner at Nova, and Carl Francis, a Nova operating partner, jointly responsible for BMP Group and RB Medical on the firm's behalf. The acquisition expands Nova's portfolio of specialized industrial and manufacturing businesses, while Andrew Industries exits its ownership of the companies. William Blair Appoints Emanuela Branchetti to Expand Biopharma Investment Banking Team Branchetti joins from Truist Securities, where she served as managing director and head of scientific affairs. To read the entire story, you must be logged in. Gridiron Capital Invests in Lawn Care Franchisor Weed Man Weed Man provides residential lawn care programs centered on fertilization and weed control, along with additional lawn care services. To read the entire story, you must be logged in. Houlihan Lokey Adds Jane Ma as Managing Director in Financial Services Group Ma joins the global investment bank after 16 years at Moelis. To read the entire story, you must be logged in. FVLCRUM Funds Purchases Fidelity Technology Services Fidelity Technology Services is a provider of military simulation training systems and services. To read the entire story, you must be logged in.

Raymond James names Dan Connolly head of technology & services investment banking. Raymond James has hired Dan Connolly as senior managing director and head of technology & services investment banking, strengthening the firm's senior leadership in the sector. The appointment is part of the firm's ongoing investment in the practice and is intended to expand its advisory capabilities across the technology sector. Connolly brings nearly three decades of investment banking experience, including work advising technology companies and financial sponsors, and will be based in Chicago. Connolly joins Raymond James after 27 years at William Blair, where he held several senior leadership positions, including co-head of global M&A, global head of technology M&A and global head of software investment banking. He was also a co-founding member of William Blair's technology investment banking team. During his career, Connolly has completed more than 300 public and private M&A transactions and financings. Lee Equity-Backed Carisk Partners Acquires FirstCare Onsite FirstCare Onsite is a provider of onsite occupational healthcare services. To read the entire story, you must be logged in. Rexel Acquires Audax-Backed GCG for $1.4B GCG provides specialty wire and cable, connectivity, power and engineered services for critical infrastructure applications. To read the entire story, you must be logged in. Gladstone Investment Backs Detroit Defense's Merger with Athenix Solutions Group Athenix capabilities span systems and software development, intelligence and cyber operations, and special mission and force readiness. To read the entire story, you must be logged in. Liberty Mutual Investments, Thayer Street Back SunHaven Management The collaboration follows LMI and Thayer Street's earlier joint investment in Grove Point Marinas. To read the entire story, you must be logged in.

Viking Therapeutics has priced an upsized $500 million concurrent public offering of common stock and convertible senior notes. The clinical-stage biopharmaceutical company will sell 7,857,143 shares at $35.00 per share and $225 million in 2% convertible senior notes due 2032. The offering size was increased from the previously announced $200 million for each component. The notes carry an initial conversion price of approximately $50.75 per share, representing a 45% premium over the public offering price. Viking estimates net proceeds of approximately $258.2 million from the common stock offering and $218 million from the note offering, after deducting underwriting discounts and expenses. The company intends to use proceeds for continued clinical development of its VK2735 and VK3019 programmes, as well as general research and development purposes. Morgan Stanley, JPMorgan, Jefferies, Leerink Partners, and William Blair are serving as joint book-running managers.